.png){kind=icon}
Return
A structure-based framework for selective inhibitor design and optimization
.png){kind=icon}
OA
AI
DOI：10.1038/s42003-025-07840-3.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Structure-based drug design aims to create active compounds with favorable properties by analyzing target structures. Recently, deep generative models have facilitated structure-specific molecular generation. However, many methods are limited by inadequate pharmaceutical data, resulting in suboptimal molecular properties and unstable conformations. Additionally, these approaches often overlook binding pocket interactions and struggle with selective inhibitor design. To address these challenges, we developed a framework called Coarse-grained and Multi-dimensional Data-driven molecular generation (CMD-GEN). CMD-GEN bridges ligand-protein complexes with drug-like molecules by utilizing coarse-grained pharmacophore points sampled from diffusion model, enriching training data. Through a hierarchical architecture, it decomposes three-dimensional molecule generation within the pocket into pharmacophore point sampling, chemical structure generation, and conformation alignment, mitigating instability issues. CMD-GEN outperforms other methods in benchmark tests and controls drug-likeness effectively. Furthermore, CMD-GEN excels in cases across three synthetic lethal targets, and wet-lab validation with PARP1/2 inhibitors confirms its potential in selective inhibitor design.
Keywords:
DRUG DESIGN
CHALLENGES
KINASE
Journal
IF:
5.1
Papers:
1.1W
Citations:
3.2W
Organization
Cited Papers
Transforming machine translation: a deep learning system reaches news translation quality comparable to human professionals.png)
NATURE COMMUNICATIONS
OAAI
NATURE COMMUNICATIONSIF15.7
OAAIShareSavePARP-2 domain requirements for DNA damage-dependent activation and localization to sites of DNA damageNUCLEIC ACIDS RESEARCHOAAI
NUCLEIC ACIDS RESEARCHIF13.1
OAAIShareSaveShareSaveShareSaveShareSaveShareSaveShareSaveShareSave
View more